Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes. Key findings include: - Marrow blast reductions observed in all evaluable patients (6 patients). - 6 of 7 patients enrolled remain on study. - Patients enrolled experienced a...
Big Rock Partners Acquisition Corp. Announces Merger with NeuroRx, Inc. Combined Company to Have an Estimated Post-Transaction Equity Value in Excess Of $500 Million (Excluding Potential Earnout Payments), Assuming A Share Price Of At Least $10.00 Per Share NeuroRx, Inc. is a clinical stage, small molecule pharmaceutical company which develops novel therapeutics...
Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures Cyclacel Pharmaceuticals has entered into a definitive securities purchase agreement with Acorn Bioventures, LP, a biotech-focused fundamental investor. - Strategic investment from single biotech-focused institutional investor - - Enables...
Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream Jaguar Health, Inc. has signed an agreement (the "Agreement") with a secured lender (the "Lender") for a non-dilutive royalty financing transaction, pursuant to which Jaguar...
ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company (agreement to merge in a stock-for-stock transaction.) Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms Together, ImmunityBio and NantKwest will have a broad,...
Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040...
1. BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial BCDA today announces that it anticipates data safety monitoring board (DSMB) verbal feedback by the end of December 15, 2020 on interim data from the Company’s pivotal Phase 3 CardiAMP Heart Failure Trial that is currently enrolling nationwide for infusion...
Arvinas Nearly Doubles on Promising Cancer Drug Results The test results show the Arvinas drugs' potential for treating breast and prostate cancer, Cantor said. Arvinas (ARVN) - Get Report shares blasted off Monday as Cantor Fitzgerald offered bullish comments on the biopharmaceutical company after it reported positive news on its breast and prostate cancer...
Solid Biosciences Announces $90 Million Private Placement Solid Biosciences has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions. The private...
ATTBF is building momentum. Easy profits!
Not clear but it could resume its breakout from this triangle.
Contextual immersion trading strategy idea. Baudax Bio is a pharmaceutical company, develops and commercializes products for hospitals and other acute care settings. The share price rose after good earnings. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and other...
This trade brings opportunity for investors looking for a a company with great fundamentals and nice risk/reward potential into end of year. As the chart shows (blue arrows) I am awaiting a buying opp around the blue trend line. From current stock price, potential risk/reward around 3.5 : 1 downside risk: $1.39 upside reward: $3.50-$5 Recent selloff after...
Long-Term pattern suggests that after previous dilution, Eyepoint's stock price went range bound for quite awhile before breaking out. This marks potential accumulation range for anyone looking to build a position in EYPT. Ranges make for good swing trade positions (especially 20%+ both ways) and a way to average down. Range low/ highs, range from $1.42 -...
Galapagos announced today a large investment and a 10-year deal with Gilead $GILD. The stock gapped due to Gilead buying 10% of Galapagos at $158/share. However, when stocks gap up on investments at a premium price, they almost always fall (see $MGI, $ARWR) An analyst at Raymond James agrees, saying he believes $GLPG stock has now fully realized his price target...
After a recent selloff in mid June 2019, Stock price went from from $6.70 down to $3.44. Cala looks to have established a double bottom. New strong uptrend suggests it has potentially capitulated from the selloff making these levels very attractive for any investors who are sidelined and looking for a good technical/ fundamental trade in biotech. Cala looks to be...
Another pharma company - with amazing correct Elliot 5 waves which you can try to ride. 1. Buy 131.32 2. Take profit: 213 3. SL: 115.90 RISK/REWARD: 5.38, potential profit 62.39%